3-[4-(Hexyloxy)-1,2,5-thiadiazol-3-yl]-1,2,5,6-tetrahydro-1-methyl-pyridine (2R,3R)-2,3-dihydroxybutanedioate (1:1)
[CAS# 152854-19-8]

Identification

• Classification: Pharmaceutical intermediate >> Heterocyclic compound intermediate >> Pyridine compound
• Name: 3-[4-(Hexyloxy)-1,2,5-thiadiazol-3-yl]-1,2,5,6-tetrahydro-1-methyl-pyridine (2R,3R)-2,3-dihydroxybutanedioate (1:1)
• Synonyms: Xanomeline tartrate
• Molecular Formula: C₁₄H₂₃N₃OS .C₄H₆O₆
• Molecular Weight: 431.50
• CAS Registry Number: 152854-19-8
• EC Number: 895-286-4
• SMILES: O=C(O)C(O)C(O)C(=O)O.N=1SN=C(C1OCCCCCC)C2=CCCN(C)C2

Properties

• Melting point: 95.5 °C

Safety Data

• Hazard Symbols: GHS07 Warning
• Risk Statements: H302
• Safety Statements: P264-P270-P301+P317-P330-P501

Hazard Classification

Hazard	Class	Category Code	Hazard Statement
Acute toxicity	Acute Tox.	4	H302

Discovery and Applications

3-[4-(Hexyloxy)-1,2,5-thiadiazol-3-yl]-1,2,5,6-tetrahydro-1-methyl-pyridine (2R,3R)-2,3-dihydroxybutanedioate (1:1) is a chemical compound with a complex structure featuring a pyridine ring, a thiadiazole moiety, and a dihydroxybutanedioate group. The substance's chemical structure incorporates functional groups such as an ether (hexyloxy) and a thiadiazole ring, which are important for its chemical reactivity and potential biological activity.

While specific references to the discovery and widespread application of this compound in the literature are limited, the components of the molecule suggest potential areas of interest. The presence of a pyridine ring, commonly associated with pharmacological activity, and a thiadiazole group, known for its antimicrobial and anti-inflammatory properties, suggests that the compound may exhibit biological activity that could be harnessed for therapeutic purposes. Thiadiazoles, in particular, have been explored for their potential in medicinal chemistry, including as antimicrobial agents and in the treatment of various diseases.

The presence of the (2R,3R)-2,3-dihydroxybutanedioate group may also imply specific interactions with metabolic pathways or enzyme systems, though further studies would be required to elucidate the full biological effects and applications of this compound.

At this time, detailed studies or specific applications of 3-[4-(Hexyloxy)-1,2,5-thiadiazol-3-yl]-1,2,5,6-tetrahydro-1-methyl-pyridine (2R,3R)-2,3-dihydroxybutanedioate (1:1) remain to be fully established in the scientific literature, and there is no strong body of evidence indicating a broad, verified use in any particular field.

Thus, while the chemical components of this molecule suggest possible applications in medicinal chemistry and related areas, further experimental research and peer-reviewed studies would be needed to verify its potential and establish its applications in these fields.

References

2024. Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials. Schizophrenia (Heidelberg, Germany).
DOI: 10.1038/s41537-024-00525-6

2024. Emerging Pharmacological Approaches for Psychosis and Agitation in Alzheimer’s Disease. CNS Drugs.
DOI: 10.1007/s40263-024-01133-9

2024. IUPHAR Review on muscarinic M1 and M4 receptors as drug treatment targets relevant to the molecular pathology of schizophrenia. Pharmacological Research.
DOI: 10.1016/j.phrs.2024.107510